MadeMed Review 2026: Is MadeMed Legit? GLP-1 Telehealth Pricing From $99, Compounded Semaglutide and Tirzepatide Programs, Men's Wellness, Peptide Therapy, and Platform Verification Guide

HOUSTON, April 21, 2026 (Newswire.com) - MadeMed Complete 2026 Overview: Telehealth Platform Pricing, Compounded GLP-1 Programs, and What Prospective Patients Should Verify

What "Claims Evaluated" Means in This Article

This article examines publicly available information about MadeMed's telehealth platform - including the company's published pricing, program descriptions, regulatory disclosures, and terms of service. The goal is straightforward: present what the company states, highlight what can be independently observed, and flag what prospective patients should verify before enrolling. This is not a product endorsement, a medical recommendation, or a third-party investigation. It is a factual breakdown designed to help you make an informed decision based on what is currently available.

TL;DR: What This Article Covers

MadeMed operates a telehealth platform offering compounded prescription medications across four categories: GLP-1 weight loss (injectable and oral semaglutide and tirzepatide), men's wellness (a 3-in-1 tadalafil/PT-141/oxytocin troche), peptide therapy (injectable and oral sermorelin), and NAD+ therapy (injectable and nasal spray). According to the company, prices start at $99 per month for oral semaglutide and go up to $269 per month for NAD+ nasal spray, with an optional $149-per-year MadeMed Club membership that the company states provides additional monthly discounts. Every medication requires an online consultation with an independent licensed clinician who determines whether a prescription is appropriate. This article breaks down what the company offers, what the regulatory context looks like, what the terms actually say, and what you should verify before making any enrollment decision.

View current MadeMed programs, pricing, and enrollment details here

Why This Information Matters Right Now (April 2026)

The compounded GLP-1 telehealth market is shifting faster than most prospective patients realize. The FDA has escalated enforcement against compounded GLP-1 marketing since September 2025, Novo Nordisk launched the first FDA-approved oral semaglutide pill in January 2026, and compounding pharmacy supply chains are narrowing as regulatory pressure increases. For anyone considering a compounded GLP-1 program, the window for evaluating options, comparing platforms, and understanding the regulatory distinctions has never been more important. This article provides the information you need to make that evaluation - based on what is publicly verifiable today.

The Compounded Medication Landscape in 2026: What Prospective Patients Should Understand First

Before evaluating any specific telehealth platform, it helps to understand the broader regulatory environment surrounding compounded prescription medications in 2026.

Compounded medications are prescription products prepared by licensed pharmacies based on individual prescriptions. They are not reviewed or approved by the FDA as finished products. They are prepared using active ingredients sourced from FDA-registered facilities under the direction of a prescribing clinician. This distinction is critical because it means compounded products have not been evaluated by the FDA for safety, effectiveness, or quality in the same manner as FDA-approved drugs.

The regulatory landscape for compounded GLP-1 medications has intensified considerably. The FDA has issued multiple rounds of warning letters to telehealth companies for marketing claims about compounded GLP-1 products that, in the agency's view, implied equivalence to FDA-approved medications or obscured the identity of the actual compounder. These enforcement actions - spanning from September 2025 through early 2026 - signal that the FDA views the marketing of compounded GLP-1 products as an ongoing priority.

This regulatory context applies across the entire compounded telehealth industry - not to any single company. Readers should factor this evolving regulatory environment into any enrollment decision, regardless of which platform they are evaluating.

These programs involve compounded prescription products, and treatment appropriateness must be determined by a licensed clinician.

How MadeMed's Platform Is Structured: Understanding the Three Entities Involved

According to the company's Terms of Use, MadeMed's telehealth model involves three distinct entities. Understanding this separation matters because it determines who is responsible for what - and who is not.

MadeMed (IDL Health LLC) functions as the telehealth platform. According to the Terms of Use, MadeMed "provides the non-clinical Site services." The company provides the technology infrastructure, customer interface, and coordination that enables the telehealth experience. The Terms explicitly state that MadeMed "does not provide medical advice or care."

Xpedicare, LLC and Its Affiliated Providers are the independent medical professionals who review patient information and make all prescribing decisions. According to the Terms of Use, Xpedicare is "an independent professional entity solely responsible for providing clinical services and making all medical decisions." Providers are independently contracted or employed by Xpedicare - not by MadeMed. The platform cannot guarantee that any individual will receive a prescription, as that determination rests entirely with the evaluating clinician.

AbsoluteRx (Partner Pharmacy) fulfills prescriptions written by the medical providers. According to the Terms, the platform provides "access to prescription fulfillment services offered by our partner pharmacies, including AbsoluteRx." The company also references partnerships with licensed, accredited compounding pharmacies in the United States, including Red Rock Pharmacy as specifically named on the About page.

This three-entity structure is common across telehealth platforms and ensures appropriate separation between the technology platform, clinical decision-making, and medication dispensing. Prospective patients should understand that enrolling with MadeMed does not guarantee a prescription - only a clinical evaluation by an independent provider. Completion of the intake process and payment does not guarantee that a prescription will be issued.

What the Company Says About Its GLP-1 Weight Loss Programs: 4 Medication Formats From $169 to $229/Month

According to the MadeMed website, the platform offers four GLP-1 medication formats for weight management. Each involves compounded prescription medications - not FDA-approved branded products like Wegovy or Mounjaro.

Injectable Semaglutide

The company describes this as a "GLP-1 Agonist: Enhanced with L-Carnitine." According to published pricing on the website, monthly plans start at $179 per month for the 0.25mg starting dose. Quarterly plans are listed as the "Most Popular" option. The website states that new patients start at 0.25mg and that the prescribing physician adjusts the dose gradually, with the price adjusting accordingly. According to the company, MadeMed Club members ($149 per year) receive a $10 per month discount.

The company references weight-loss outcomes associated with semaglutide, including a figure of "15-20% average body weight loss." Those figures are tied to broader clinical literature about FDA-approved branded semaglutide products studied in formal clinical trials and should not be interpreted as established outcomes for the compounded formulations dispensed through this telehealth platform. Compounded semaglutide products are not FDA-approved finished drugs and have not been independently evaluated by the FDA for safety, effectiveness, or quality.

Compounded medications are typically prescribed when a clinician determines that a patient's needs are not adequately met by commercially available FDA-approved products - a framework established under Section 503A of the Federal Food, Drug, and Cosmetic Act. This distinction is important for understanding why compounded GLP-1 formulations exist alongside branded alternatives.

Injectable Tirzepatide

The company describes this as a "GLP-1/GIP Dual Agonist: Enhanced with L-Carnitine" and presents it as a higher-efficacy option in its marketing materials. According to published pricing, monthly plans start at $189 per month for the 2.5mg starting dose. MadeMed Club members receive a stated $20 per month discount on tirzepatide programs. The company references a figure of "20-25% average body weight loss" for tirzepatide.

As with the semaglutide figures, these percentages are associated with FDA-approved branded tirzepatide products studied in clinical trials - not the compounded formulation offered through this platform. Prospective patients should not assume that compounded versions will produce equivalent results. The evaluating clinician determines whether tirzepatide or semaglutide is more appropriate based on individual health factors.

Oral Semaglutide

The company offers a sublingual (under the tongue) semaglutide tablet format. According to published pricing, monthly plans start at $169 per month for the 1mg starting dose. The website describes this as a daily tablet with a 30-day supply shipped monthly.

An important regulatory note: On December 22, 2025, the FDA approved Novo Nordisk's Wegovy tablet (oral semaglutide 25 mg) as the first oral GLP-1 receptor agonist for chronic weight management, with a national launch in January 2026. That is an FDA-approved finished drug product. The oral semaglutide offered through MadeMed is a compounded sublingual formulation - it is not the same product, does not use the same proprietary absorption technology, and has not been independently evaluated by the FDA for bioavailability, dosing equivalence, or absorption characteristics relative to the FDA-approved version.

Oral Tirzepatide

The company offers a sublingual tirzepatide tablet format described as "Dual GLP-1/GIP action in a daily tablet." According to published pricing, monthly plans start at $229 per month for the 3mg starting dose, with MadeMed Club members receiving a stated $20 per month discount.

There is currently no FDA-approved oral tirzepatide finished drug product. The oral tirzepatide offered through MadeMed is a compounded sublingual format. Prospective patients should not interpret the availability of this format as equivalence to any FDA-approved injectable product. The evaluating clinician determines whether this delivery format is appropriate based on individual health factors and clinical judgment.

These programs involve compounded prescription products, and treatment appropriateness must be determined by a licensed clinician.

See current GLP-1 program pricing, dose options, and enrollment details on the official MadeMed website

What the Company Says About Its Men's Wellness Program

MadeMed offers a compounded sublingual troche containing three active ingredients: tadalafil, PT-141 (bremelanotide), and oxytocin. The company describes this as a "3-in-1 Formula" that addresses what it calls "Performance + Desire + Connection."

According to published pricing, the 5mg starting dose is listed at $119 per month for 8 troches. MadeMed Club members receive a stated $10 per month discount.

The company's FAQ states that "PT-141 is FDA-approved for low sexual desire." This requires clarification: bremelanotide (marketed under the brand name Vyleesi) received FDA approval specifically as a subcutaneous injection for hypoactive sexual desire disorder (HSDD) in premenopausal women. The compounded troche format offered through MadeMed is not the same product, is not FDA-approved, and the approved indication does not extend to male patients or to other delivery formats. Any use in this compounded formulation would be considered off-label, with treatment appropriateness determined by the evaluating clinician.

The company's FAQ also describes a clinical maximum of 8 doses per month for PT-141, which the company states is "established in FDA guidelines for the brand-name version (Vyleesi)." The dosing limitation exists because PT-141 can temporarily affect blood pressure.

These are compounded prescription medications. Not all individuals will qualify. The prescribing clinician determines whether treatment is appropriate based on individual medical history, current medications, and cardiovascular status.

What the Company Says About Its Peptide Therapy Programs

MadeMed offers sermorelin in two formats: injectable and oral (sublingual tablet). The company describes sermorelin as a "growth hormone-releasing peptide" that supports "deep sleep, recovery, and lean body composition."

According to published pricing, injectable sermorelin (9mg/3mL) starts at $199 per month, and oral sermorelin (1000mcg sublingual tablets) starts at $149 per month. Both formats require a board-certified physician consultation. The injectable format additionally requires an IGF-1 blood test before prescribing, which the company states can be completed at any Labcorp or Quest location.

The claims about sleep, recovery, and body composition represent the company's marketing positioning for sermorelin programs. Sermorelin is a growth hormone-releasing hormone (GHRH) analog - it is a compounded prescription product, not an FDA-approved finished drug for these marketed purposes. Prospective patients should discuss expected outcomes and realistic timelines with their evaluating clinician.

What the Company Says About Its NAD+ Therapy Programs

MadeMed offers NAD+ in two formats: injectable and nasal spray. The company describes these programs as providing "cellular energy support for mental clarity, healthy aging, and sustained vitality."

According to published pricing, NAD+ injections (1000mg, 8 injections per month) start at $249 per month, and NAD+ nasal spray (500mg/15mL, 30-day supply) starts at $269 per month. Both formats require a CMP blood test before prescribing. MadeMed Club members receive a stated $20 per month discount on both NAD+ programs.

The company references "Patented NanoNAD+ Technology" for both products. No publicly verifiable patent documentation was identified at the time of this review to substantiate this claim, and it should be treated as the company's marketing positioning until independently confirmed. The terms "cellular rejuvenation," "mental clarity," and "healthy aging" represent the company's positioning language and should not be interpreted as clinically established treatment outcomes for these compounded formulations.

These are compounded prescription medications. Treatment appropriateness must be determined by a licensed clinician based on individual health factors.

What the Company Says About Pricing and the MadeMed Club Membership

According to the company's website, MadeMed operates an optional annual membership called the MadeMed Club, priced at $149 per year. The company compares this model to a "Costco for healthcare" and states that members receive discounts ranging from $10 to $20 per month depending on the program.

Based on the company's published membership pricing and discount structure, a patient on a program with a stated $20 monthly discount would mathematically offset the annual membership cost in under eight months, assuming pricing and participation remain unchanged. This is an arithmetic example based on published pricing - not a guaranteed savings promise. Verify current membership terms and discount amounts on the official website before enrolling.

The company states it does not accept insurance and describes this as enabling "transparent, direct-to-patient pricing without the complexities of insurance claims." According to the website, the company does not currently accept FSA or HSA cards for payment.

Insurance coverage for compounded prescription products varies. Many direct-to-consumer prescription products are not covered by traditional insurance plans, but coverage policies differ by insurer and plan. Always confirm benefits directly with your insurer.

All pricing mentioned in this article was sourced from the company's published website and was accurate at the time of publication (April 2026). Pricing is subject to change without notice. Always verify current pricing and terms on the official MadeMed website before making enrollment decisions.

Check current MadeMed Club membership pricing and program discounts on the official website

MadeMed Program-by-Program Pricing Summary (April 2026)

The following pricing breakdown is based on the company's published website as of April 2026. All prices represent starting doses and are subject to change. Dose increases adjust the price accordingly. Verify current pricing on the official website before enrolling.

Injectable Semaglutide (0.25mg start): $179/month (monthly plan). MadeMed Club discount: $10/month. Quarterly billing available. Includes L-Carnitine, physician consultation, overnight shipping, and injection supplies.

Injectable Tirzepatide (2.5mg start): $189/month (monthly plan). MadeMed Club discount: $20/month. Quarterly billing available. Includes L-Carnitine, physician consultation, overnight shipping, and injection supplies.

Oral Semaglutide (1mg start): $169/month (monthly plan). MadeMed Club discount: $10/month. Quarterly billing available. 30 sublingual tablets per month. No needles.

Oral Tirzepatide (3mg start): $229/month (monthly plan). MadeMed Club discount: $20/month. Quarterly billing available. 30 sublingual tablets per month. No needles.

3-in-1 Men's Wellness Troche (5mg start): $119/month (monthly plan). MadeMed Club discount: $10/month. 8 troches per month (clinical maximum for PT-141).

Injectable Sermorelin (9mg/3mL): $199/month (monthly plan). MadeMed Club discount: $10/month. IGF-1 blood test required before prescribing.

Oral Sermorelin (1000mcg): $149/month (monthly plan). MadeMed Club discount: $10/month. 30 sublingual tablets per month. No needles.

NAD+ Injections (1000mg): $249/month (monthly plan). MadeMed Club discount: $20/month. 8 injections per month. CMP blood test required before prescribing.

NAD+ Nasal Spray (500mg/15mL): $269/month (monthly plan). MadeMed Club discount: $20/month. 30-day supply. CMP blood test required before prescribing.

MadeMed Club Membership: $149/year (optional). Unlocks all program discounts listed above.

According to the company, all programs include a board-certified physician consultation. If the evaluating clinician determines that a prescription is not appropriate, the company states the patient receives a full refund minus a $39 doctor visit fee. All pricing is subject to change - verify current terms before enrolling.

What the Terms Say About Enrollment, Billing, and Cancellation: FAQ vs. Terms of Use Compared

Understanding what happens after enrollment requires reading both the company's FAQ language and the governing Terms of Use - because the two sources frame the same policies differently.

The enrollment process, according to the website, involves four steps: completing a health questionnaire (described as taking approximately 5 minutes), physician review within 24 hours, prescription fulfillment and shipping, and ongoing treatment with progress tracking. The company states that if a prescription is not written, the patient receives a full refund minus a $39 doctor visit fee.

Regarding billing notifications, the company's FAQ states: "We email you 7 days before every charge with the exact amount and easy options to pause, skip, or cancel." The FAQ also states patients will "always" know the new price before shipping when doses are adjusted.

Regarding cancellation, the FAQ describes "one click from your dashboard" with "no phone calls, no chat queues, no guilt trips." The FAQ also states that when pausing, "billing stops immediately. Not 'next cycle' - immediately."

However, the governing Terms of Use state: "You can cancel your subscription at any time by emailing support@mademed.com or through your account portal. Cancellations will be effective at the end of the current billing period. We do not offer prorated refunds."

Prospective patients should review both the FAQ and the governing Terms of Use directly before enrolling. Where there is any ambiguity between FAQ language and Terms language, the Terms of Use are the legally binding document. Understanding the distinction between "immediate pause" and "cancellation effective at the end of the current billing period" is important for managing financial expectations.

Regarding returns, the company's Returns Policy is clear: "For the safety of all our patients, federal and state laws prohibit us from accepting returns on medication once it has been dispensed by the pharmacy." In other words, all sales of prescription products are final and non-refundable once the pharmacy has dispensed the medication.

What the Website Says About Side Effects and Candidacy

The company's FAQ sections include information about potential side effects and candidacy criteria for various programs. A high-level overview based on the company's published information is provided below - this is not medical advice, and the following does not represent a complete list of risks or precautions.

GLP-1 medications: According to the company's FAQ, common side effects include nausea, diarrhea, and decreased appetite. The company notes that serious but rare side effects can include pancreatitis and gallbladder issues. The FAQ states that tirzepatide is "generally prescribed for adults with a BMI of 30 or greater, or a BMI of 27 or greater with a weight-related condition like hypertension" and notes contraindications including personal or family history of medullary thyroid cancer, MEN 2, or pregnancy and breastfeeding.

Men's wellness troche: According to the company's FAQ, common side effects include headache, flushing, and nasal congestion from the tadalafil component, and nausea or flushing from PT-141. The FAQ specifically warns that tadalafil "should NOT be taken with nitrates (nitroglycerin, isosorbide) or alpha-blockers due to serious blood pressure interactions" and that PT-141 "should not be used by people with uncontrolled high blood pressure or cardiovascular disease."

GLP-1 weight regain: The company's FAQ includes an unusually candid disclosure: "Weight regain is common after stopping GLP-1/GIP medications. Your appetite will return to baseline, and you may regain some or all of the weight lost." This level of transparency about post-discontinuation outcomes is worth noting as a positive differentiator.

Potential side effects and contraindications should be reviewed with a licensed healthcare provider before starting treatment. The information above is sourced from the company's published FAQ and does not replace individualized medical guidance from the evaluating clinician.

What the Website Says About State Availability: 40 States Served, 10 Not Currently Available

According to the company's website, MadeMed currently serves patients in 40 states. The company lists the following states as served: Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Vermont, Washington, West Virginia, Wisconsin, and Wyoming.

The company states it does not currently serve Alabama, Alaska, Arkansas, Hawaii, Massachusetts, Missouri, New Mexico, New York, South Carolina, or Virginia, and notes it is "working to expand availability to more states."

State availability may change. Verify current coverage directly with the company before starting the enrollment process.

How to Verify MadeMed's Platform Standing: 6 Observable Markers to Check Before Enrolling

When people search for whether a telehealth platform is legitimate, the more useful question is whether the company appears to operate with identifiable terms, named service structures, disclosed program pricing, licensed-provider review, and pharmacy fulfillment disclosures. Here is what is publicly observable about MadeMed.

Identifiable business entity: According to the Terms of Use, MadeMed operates as IDL Health LLC, with a listed business address at 9668 Westheimer Rd Suite 200 #32, Houston, TX 77063.

Named medical group separation: The Terms identify Xpedicare, LLC as the independent professional entity responsible for clinical services. The named medical director on the About page is Dr. Thai Pham, described as a Brown University-educated internist with over 25 years of clinical experience.

Named partner pharmacy: The Terms reference AbsoluteRx as a partner pharmacy. The About page additionally references Red Rock Pharmacy.

Certification display: The company displays a LegitScript Certified badge and an Authorize.net Preferred Reseller badge on its website. Certification status, scope, and current standing should be independently verified through LegitScript's verification portal and Authorize.net's records before relying on them as trust signals - certifications do not guarantee clinical outcomes or service quality.

Published contact information: According to the company's website, customer support is available by phone at +1 (800) 582-1428 and by email at support@mademed.com.

Transparent program pricing: All programs display dose-based pricing on the website, including both member and non-member rates.

These markers suggest an identifiable, structured operation - but observable website elements are not a substitute for independent due diligence. Prospective patients should verify certification status, review the governing Terms of Use and Returns Policy, confirm state-specific availability, and consult with a healthcare provider before making enrollment decisions.

These programs involve compounded prescription products, and treatment appropriateness must be determined by a licensed clinician.

Review MadeMed's programs, pricing structure, and enrollment process on the official website

Who MadeMed's Programs May Align Well With

Adults exploring compounded GLP-1 options without insurance coverage: According to the company, all programs operate on a cash-pay basis without insurance billing. For individuals whose insurance does not cover branded GLP-1 medications like Wegovy or Mounjaro, compounded alternatives through telehealth platforms represent one potential access pathway - though compounded products have not been evaluated by the FDA as finished drugs.

People who prefer needle-free medication formats: The company offers oral sublingual tablet options for semaglutide, tirzepatide, and sermorelin, as well as a nasal spray option for NAD+. For individuals with needle aversion, these delivery formats may be worth discussing with a clinician - though sublingual bioavailability may differ from injectable formats.

Adults seeking multiple treatment categories from a single platform: MadeMed's coverage across GLP-1 weight management, men's wellness, peptide therapy, and NAD+ therapy on one platform may offer convenience for individuals interested in multiple treatment categories. Each program requires separate clinical evaluation.

Other Options May Be Preferable For People Who

Want FDA-approved branded medications: MadeMed's current offerings are compounded formulations, not FDA-approved branded products. Individuals who prefer FDA-approved products should explore platforms that offer Wegovy, Mounjaro, Zepbound, or other branded options - potentially through insurance coverage or manufacturer savings programs.

Require in-person clinical supervision: All MadeMed consultations are conducted through a secure online platform, not in-person visits. Individuals with complex medical histories, multiple medications, or conditions requiring physical examination may benefit from an in-person provider relationship.

Live in states not currently served: MadeMed does not currently serve patients in 10 states. Individuals in those states would need to explore alternative platforms.

Prioritize insurance-reimbursable treatment: According to the company, MadeMed does not accept insurance, FSA, or HSA payments. Individuals for whom insurance coverage is a priority should explore providers that bill insurance directly.

Questions to Ask Yourself Before Enrolling

Before choosing any telehealth platform for compounded prescription medications, take a moment to consider where you stand on these questions:

Have you discussed compounded versus FDA-approved medication options with a healthcare provider you trust? Do you understand that compounded medications are not FDA-approved finished products and have not been evaluated by the FDA for safety, effectiveness, or quality? Have you read through the platform's Terms of Use, Returns Policy, and subscription billing structure - not just the marketing pages? Have you confirmed that the platform serves your state? Have you checked whether the medications under consideration could conflict with your current prescriptions or health conditions? And are you comfortable with the cash-pay pricing structure, given that insurance reimbursement may not be available?

Your answers help determine whether a telehealth platform offering compounded prescription medications aligns with your specific healthcare needs and financial situation.

The Regulatory Context: What the Industry Landscape Means for Prospective Patients

The compounded telehealth GLP-1 industry has faced increasing regulatory attention since 2025, and that trend has only accelerated. Prospective patients should be aware of the broader dynamics affecting all platforms in this space - not just MadeMed.

The FDA has issued multiple rounds of warning letters to telehealth companies marketing compounded GLP-1 products. The primary enforcement concerns have centered on marketing claims that imply equivalence to FDA-approved products and branding practices that obscure the identity of the actual compounder. The FDA has stated that compounded drugs "are not FDA-approved" and that companies should not "try to compound drugs in a way that circumvents FDA's approval process."

Additionally, the Novo Nordisk patent litigation against Hims & Hers in early 2026 - which ultimately resulted in a partnership agreement - and a coalition letter from 35 state attorneys general about AI-generated weight-loss advertising both signal that the regulatory and legal landscape for compounded telehealth products continues to evolve.

This does not mean that compounded medications are inherently illegitimate. Section 503A of the Federal Food, Drug, and Cosmetic Act allows licensed pharmacies to compound medications to meet individual patient needs when a commercially available product is unavailable or unsuitable. However, the distinction between individual patient-specific compounding and mass-marketed compounded products has become a focal point for regulators.

Readers should review the most current information about any telehealth platform's compliance and regulatory standing before proceeding with enrollment.

Final Assessment: What to Verify Before Making a Decision

What the company offers: MadeMed operates a multi-category telehealth platform covering compounded GLP-1 weight loss medications (injectable and oral semaglutide and tirzepatide), a 3-in-1 men's wellness troche (tadalafil/PT-141/oxytocin), peptide therapy (injectable and oral sermorelin), and NAD+ therapy (injectable and nasal spray). According to published pricing, programs range from $99 to $269 per month depending on medication, dose, and membership status.

What the platform structure shows: The company operates with identifiable business registration (IDL Health LLC), named medical group separation (Xpedicare, LLC), named partner pharmacies (AbsoluteRx, Red Rock Pharmacy), LegitScript Certified and Authorize.net Preferred Reseller badges, published contact information, and transparent dose-based pricing.

What prospective patients should verify: Certification claims through independent verification portals. The governing Terms of Use and Returns Policy - not just the FAQ. Current state availability. Whether compounded formulations are appropriate for their individual health situation, as determined by a licensed clinician - not by marketing materials. The distinction between compounded products and FDA-approved branded medications. Current regulatory developments affecting the compounded telehealth industry.

Important Note: The compounded telehealth medication industry has been under increased regulatory scrutiny in recent years. The FDA has issued multiple rounds of warning letters to telehealth companies regarding marketing practices for compounded GLP-1 products. Prospective patients should review the most current information about any platform's compliance, regulatory standing, and product offerings before proceeding with enrollment.

View current MadeMed programs, pricing, and enrollment information on the official website

What MadeMed Does Not Currently Offer

Understanding what a platform does not provide is just as important as understanding what it does. Based on the company's published website and program listings, the following are not currently available through MadeMed:

FDA-approved branded GLP-1 medications: MadeMed does not currently list Wegovy, Ozempic, Mounjaro, or Zepbound among its available programs. All GLP-1 offerings are compounded formulations. Patients who specifically want FDA-approved branded products will need to explore other telehealth platforms or traditional healthcare providers.

Insurance billing or FSA/HSA acceptance: The company explicitly states it does not accept insurance or FSA/HSA payments. All programs operate on a cash-pay basis.

In-person clinical visits: All consultations are conducted through the online platform. There is no brick-and-mortar clinic component.

Service in all 50 states: According to the company, 10 states are not currently served, including New York, Massachusetts, and Virginia.

These are not necessarily drawbacks - they reflect the company's current business model and scope. But they are important factors for prospective patients to weigh against their individual needs and preferences.

Frequently Asked Questions

What is MadeMed?

According to the company's Terms of Use, MadeMed (operated by IDL Health LLC) is a telehealth platform that connects patients with independent licensed clinicians through Xpedicare, LLC for medical evaluation and prescription fulfillment. The platform itself does not provide medical care. Clinical decisions, including whether to prescribe medication, are made by independent providers. Verify current platform details on the official website before enrolling.

What types of medications does MadeMed offer?

According to the company's website, MadeMed offers compounded prescription medications across four categories: GLP-1 weight loss (semaglutide and tirzepatide in injectable and oral formats), men's wellness (a 3-in-1 tadalafil/PT-141/oxytocin troche), peptide therapy (sermorelin in injectable and oral formats), and NAD+ therapy (injectable and nasal spray). All are compounded formulations - not FDA-approved branded products. Verify current program availability on the official website.

Are MadeMed's medications FDA-approved?

No. According to the company's Terms of Use: "You acknowledge and agree that certain prescription medications available through the platform may be prepared by a compounding pharmacy. Compounded drugs are not approved by the Food and Drug Administration (FDA) and are not evaluated for safety or efficacy." The active ingredients used in compounded formulations may be sourced from FDA-registered facilities, but the finished compounded products themselves are not FDA-approved.

How does MadeMed's pricing work?

According to the company's website, pricing is dose-based and displayed transparently for each program. An optional MadeMed Club membership ($149 per year) provides additional discounts ranging from $10 to $20 per month depending on the program. Verify current pricing directly on the official website, as pricing is subject to change without notice.

What is the MadeMed Club?

According to the company, the MadeMed Club is an optional annual membership ($149 per year) that provides reduced pricing on medication programs. The company compares this to a "Costco membership for healthcare." Membership terms and discount amounts should be verified on the official website before enrolling.

Can I cancel my MadeMed subscription?

The company's FAQ describes dashboard-based cancellation with "no phone calls, no chat queues." However, the governing Terms of Use state that "cancellations will be effective at the end of the current billing period" and that prorated refunds are not offered. Prospective patients should review both the FAQ and the Terms of Use to understand how cancellation works before enrolling.

Does MadeMed accept insurance?

According to the company's website, MadeMed does not accept insurance and does not currently accept FSA or HSA cards for payment. All programs operate on a cash-pay basis. Insurance coverage for compounded prescription products varies by insurer and plan - always confirm benefits directly with your insurance provider.

What states does MadeMed serve?

According to the company's website, MadeMed currently serves patients in 40 states. The company does not currently serve Alabama, Alaska, Arkansas, Hawaii, Massachusetts, Missouri, New Mexico, New York, South Carolina, or Virginia. State availability may change - verify current coverage on the official website before starting the enrollment process.

Is MadeMed legitimate?

The company operates with identifiable business registration, named medical group separation, named partner pharmacies, published contact information, and displayed certification badges. These are observable markers that prospective patients can verify independently. However, observable website elements are not a substitute for independent due diligence. Verify certification claims, review governing Terms, and consult with a healthcare provider before making enrollment decisions.

What happens if I'm not prescribed medication?

According to the company's website, if a prescription is not written following the clinical evaluation, the patient receives a full refund minus a $39 doctor visit fee. This consultation fee covers the professional time and medical judgment of the evaluating clinician, regardless of the prescribing outcome.

How much does MadeMed cost per month?

According to the company's published website, monthly pricing ranges from $99 per month (oral semaglutide at the lowest available dose with MadeMed Club membership) to $269 per month (NAD+ nasal spray). GLP-1 weight loss programs range from $169 to $229 per month at starting doses. The optional MadeMed Club membership costs $149 per year and reduces monthly costs by $10 to $20 depending on the program. Prices increase as doses are titrated upward. Always verify current pricing on the official website before enrolling.

Does MadeMed offer oral GLP-1 tablets or only injections?

According to the company's website, MadeMed offers both injectable and oral (sublingual tablet) formats for semaglutide and tirzepatide. The oral formats are compounded sublingual tablets - not the same as FDA-approved oral semaglutide (Wegovy pill). The compounded sublingual versions have not been evaluated by the FDA for bioavailability or absorption equivalence. The evaluating clinician determines which delivery format is appropriate based on individual health factors.

Is MadeMed available in my state?

According to the company's website, MadeMed currently serves 40 states. It does not currently serve Alabama, Alaska, Arkansas, Hawaii, Massachusetts, Missouri, New Mexico, New York, South Carolina, or Virginia. State availability is subject to change - verify current coverage before beginning the enrollment process.

Contact Information

For questions before or during enrollment, according to the company's website, MadeMed offers the following customer support options:

Phone: +1 (800) 582-1428

Email: support@mademed.com

Business Entity: IDL Health LLC (d/b/a MadeMed)

Address: 9668 Westheimer Rd Suite 200 #32, Houston, TX 77063

View current MadeMed programs and enrollment options on the official website

Disclaimers

Content and Medical Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. The descriptions of potential benefits are not guarantees and are not a substitute for an individualized medical evaluation. The medications discussed are compounded prescription products that require evaluation by a licensed clinician. The information provided here does not replace the professional judgment of your healthcare provider.

Professional Medical Disclaimer: This article is educational and does not constitute medical advice. Compounded prescription medications are not a substitute for prescribed medical treatment evaluated through traditional clinical channels. If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting any new prescription treatment. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician's guidance and approval.

Compounded Medication Notice: The medications discussed in this article are compounded prescription products prepared by licensed pharmacies based on individual prescriptions. Compounded medications are not reviewed or approved by the FDA as finished products. They are prepared using active ingredients sourced from FDA-registered facilities under the direction of a prescribing clinician. Compounded products have not been evaluated by the FDA for safety, effectiveness, or quality in the same manner as FDA-approved drugs.

Results May Vary: Individual results will vary based on factors including age, baseline health condition, metabolic factors, consistency of use, genetic factors, current medications, lifestyle factors, and other individual variables. Weight-loss percentages cited in this article are associated with FDA-approved branded products studied in formal clinical trials and should not be interpreted as expected outcomes for compounded formulations. Results are not guaranteed.

FTC Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All descriptions are based on publicly available information from the company's official website, published Terms of Use, and general industry context.

Pricing Disclaimer: All prices, program details, membership terms, and promotional information mentioned were sourced from the company's published website and were accurate at the time of publication (April 2026) but are subject to change without notice. Always verify current pricing, program availability, and terms on the official MadeMed website before making enrollment decisions.

Publisher Responsibility: The publisher of this article has made every effort to ensure accuracy at the time of publication based on publicly available information. The publisher does not accept responsibility for errors, omissions, or outcomes resulting from the use of the information provided. Readers are encouraged to verify all details directly with MadeMed and their healthcare provider before making decisions.

Insurance Coverage Note: Many direct-to-consumer prescription products are not covered by traditional insurance plans, but coverage policies vary. According to the company, MadeMed does not accept insurance or FSA/HSA payments. Always confirm benefits directly with your insurer. Some HSA/FSA plans may reimburse qualifying expenses - check your specific plan rules.

Regulatory Context Disclaimer: The compounded telehealth medication industry has been under increased regulatory scrutiny. The FDA has issued multiple rounds of warning letters to telehealth companies regarding marketing practices for compounded GLP-1 and other products. This regulatory environment is evolving and may affect program availability, product offerings, and industry practices. Readers should review the most current information about any platform's compliance and regulatory standing before making enrollment decisions.

SOURCE: MadeMed

Source: MadeMed